Stock CYCC CYCLACEL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Cyclacel Pharmaceuticals, Inc.

Equities

CYCC

US23254L8019

Delayed Nasdaq
Other stock markets
 21:00:00 08/05/2024 BST 		5-day change 1st Jan Change
2.32 USD +9.95% Intraday chart for Cyclacel Pharmaceuticals, Inc. -12.45% -13.11%
05-02 Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding CI
04-30 Top Midday Gainers MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Midday Gainers
MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of FOMC Meeting
MT
Cyclacel Pharmaceuticals Withdraws Securities Offering SEC Filing
DJ
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer
CI
Earnings Flash (CYCC) CYCLACEL Posts Q4 Revenue $31,000
MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
CI
Reverse Split: 1 of 15
FA
Earnings Flash (CYCC) CYCLACEL Reports Q3 Revenue $16,000
MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023
CI
Earnings Flash (CYCC) CYCLACEL Posts Q2 Revenue $373,000
MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023
CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
Earnings Flash (CYCC) CYCLACEL Posts Q3 Loss $-0.42
MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2022
CI
Cyclacel Pharmaceuticals, Inc. Reports Preliminary Data from its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients with Solid Tumors and Lymphoma at ENA 2022
CI
Earnings Flash (CYCC) CYCLACEL Reports Q2 Loss $-0.46, vs. Street Est of $-0.54
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYCC Stock
  4. News Cyclacel Pharmaceuticals, Inc.
  5. Highlights